CCC Project - Atrial Fibrillation

NCT ID: NCT02309398

Last Updated: 2021-01-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

67028 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-01-31

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to develop and implement quality improvement programs for the treatment of atrial fibrillation (AF) in China based on the successful experience of the AHA-Get with the Guidelines program. This program will use data collection, analysis, feedback, and process improvement to extend the use of evidence-based guidelines throughout the healthcare system and improve patient care of atrial fibrillation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Hospitalized patients with discharge diagnosis as atrial fibrillation in 150 tertiary and 100 secondary hospitals.

Exclusion Criteria

None
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

American Heart Association

OTHER

Sponsor Role collaborator

Chinese Society of Cardiology

OTHER

Sponsor Role collaborator

Beijing Institute of Heart, Lung and Blood Vessel Diseases

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dong ZHAO

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dong Zhao, Ph. D

Role: PRINCIPAL_INVESTIGATOR

Beijing Institute of Heart, Lung and Blood Vessel Diseases

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Beijing An Zhen Hospital

Beijing, , China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

References

Explore related publications, articles, or registry entries linked to this study.

Hao Y, Liu J, Smith SC, Huo Y, Fonarow GC, Ge J, Liu J, Taubert KA, Morgan L, Guo Y, Zhou M, Zhao D, Ma C; CCC-AF Investigators. Rationale and design of the improving Care for Cardiovascular Disease in China (CCC) project: a national registry to improve management of atrial fibrillation. BMJ Open. 2018 Jul 5;8(7):e020968. doi: 10.1136/bmjopen-2017-020968.

Reference Type RESULT
PMID: 29980544 (View on PubMed)

Tong XY, Lin J, Sun ZQ, He Q, Zhan Y, Jiang CX, Tang RB, Sang CH, Ning M, Jia CQ, Feng L, Wang W, Zhao X, Li CY, Li SN, Guo XY, Liu T, Li MM, Yang N, Hao YC, Liu J, Liu J, Xie J, Long DY, Dong JZ, Zhao D, Ma CS. Low-density lipoprotein cholesterol levels and in-hospital bleeding in patients with atrial fibrillation: findings from CCC-AF project. Front Cardiovasc Med. 2025 Jun 12;12:1574796. doi: 10.3389/fcvm.2025.1574796. eCollection 2025.

Reference Type DERIVED
PMID: 40574812 (View on PubMed)

Yang N, Sun Z, Liu J, Hao Y, Long D, Zhao D, Liu J; CCC-AF Investigators. Impact of insurance coverage for non-vitamin K antagonist oral anticoagulants on quality of care and care disparities in patients hospitalised with atrial fibrillation in tertiary hospitals in China: interrupted time series analysis. BMJ Open. 2025 Feb 22;15(2):e088539. doi: 10.1136/bmjopen-2024-088539.

Reference Type DERIVED
PMID: 39986999 (View on PubMed)

Xia Y, Jiang J, Fan F, Pan Y, Zhou J, Zhang Y, Li J, Liu J, Yang N, Hao Y, Zhao D, Liu J, Ma C, Huo Y; CCC-AF investigators. Prevalence, Characteristics, and Treatment Strategy of Different Types of Heart Failure in Patients With Nonvalvular Atrial Fibrillation. J Am Heart Assoc. 2024 Oct;13(19):e033941. doi: 10.1161/JAHA.123.033941. Epub 2024 Sep 30.

Reference Type DERIVED
PMID: 39344652 (View on PubMed)

Lin J, Long D, Jiang C, Sang C, Tang R, Li S, Wang W, Guo X, Ning M, Sun Z, Yang N, Hao Y, Liu J, Liu J, Du X, Morgan L, Fonarow GC, Smith SC Jr, Lip GYH, Zhao D, Dong J, Ma C; CCC-AF investigators. Oral anti-coagulants use in Chinese hospitalized patients with atrial fibrillation. Chin Med J (Engl). 2024 Jan 20;137(2):172-180. doi: 10.1097/CM9.0000000000002915. Epub 2023 Dec 22.

Reference Type DERIVED
PMID: 38146256 (View on PubMed)

He P, Pan Y, Jiang J, Fan F, Zhou J, Xia Y, Liu J, Yang N, Hao Y, Li J, Liu J, Zhao D, Huo Y; CCC-AF investigators. In-hospital therapies and determinants of treatment strategy selection in patients with atrial fibrillation and left ventricular systolic dysfunction in China: a retrospective study based on the Improving Care for Cardiovascular Disease in China-Atrial Fibrillation (CCC-AF) project, 2015-2019. BMJ Open. 2023 Jun 5;13(6):e070070. doi: 10.1136/bmjopen-2022-070070.

Reference Type DERIVED
PMID: 37277219 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CCC-AF-2014

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.